AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36060925
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard hydration therapy only)
Trial: 36214036
Drug: Home delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home delivery of chronic medication
Trial: 33788457
Drug: Electrothermal acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrothermal acupuncture therapy applied at Guanyuan (CV 4), Qihai (CV 6), Zusanli (ST 36), Hegu (LI 4), Sanyinjiao (SP 6), 30 min each treatment, once a day for 5 days
Trial: 33788457
Drug: Opioid painkillers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioid painkillers (oxycodone hydrochloride prolonged-release tablet or morphine sulfate sustained-release tablet)
Trial: 35311718
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (MT) 5 times a week for 30 minutes each time over a period of 3 weeks
Trial: 35311718
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CT) receiving medication and routine rehabilitation training
Trial: 32949864
Drug: Targeted treatment
RxNorm normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted treatment (TT) with fenbendazole at 22, 27 and 36 weeks post‐placement (WPP)
Trial: 32949864
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CT) at 27 WPP
Trial: 35476239
Drug: Dynamic real-time
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dynamic real-time feedback via daily computer-generated email to providers regarding their HCAHPS performance and peer comparison.
Trial: 35398397
Drug: Internet- and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet- and mobile-based intervention (IMI) + treatment as usual (TAU)
Trial: 33560104
Drug: Bilateral lower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral lower extremity DUS surveillance on days 1, 3, and 7 and weekly during hospitalization (US)
Trial: 33217877
Drug: Oral Jianweixiaoshi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Jianweixiaoshi tablets
Trial: 34907021
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (25 mg/kg body weight per day) for 12 months
Trial: 33885203
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (21 mg once daily with taper)
Trial: 32310273
Drug: Pitavastatin therapy
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin therapy in PWH
Trial: 32310273
Drug: Pitavastatin therapy
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin therapy in non-HIV participants
Trial: 35422024
Drug: Bisoprolol (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (1.25 mg tablets, titrated up to a maximum of 5 mg daily over 4-7 weeks)
Trial: 34275697
Drug: De-escalation therapy
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation therapy
Trial: 34275697
Drug: De-escalation to
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De-escalation to clopidogrel or low-dose prasugrel
Trial: 33509043
Drug: St. Thomas
RxNorm normalized name: St. Thomas lidpod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. Thomas solution
Trial: 32350749
Drug: Cannabidiol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol (20 mg/kg/day)
Trial: 32966832
Drug: Sonodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonodynamic therapy (SDT)
Trial: 35561480
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (30 mg/day elemental zinc)
Trial: 35918587
Drug: Oniria® (1.98
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oniria® (1.98 mg prolonged-release melatonin)
Trial: 35918587
Drug: Immediate-release tablets
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tablets (IRT)
Trial: 34163127
Drug: ISVCZ 50ug/0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISVCZ 50ug/0.1 mL
Trial: 34163127
Drug: ISAMB 5ug/0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISAMB 5ug/0.1 mL
Trial: 34163127
Drug: ISNTM 10ug/0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISNTM 10ug/0.1 mL
Trial: 34752681
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) with maintenance antidepressant medication (mADM)
Trial: 34752681
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) with discontinued maintenance antidepressant medication (mADM)
Trial: 34752681
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) with continued maintenance antidepressant medication (mADM)
Trial: 33757137
Drug: Increased nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased nasal flow therapy (8-10 L/min)
Trial: 33757137
Drug: Standard nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard nasal flow therapy (5-7 L/min)
Trial: 35030133
Drug: Intraoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous bolus dose of Dexmedetomidine
Trial: 36193094
Drug: L. crispatus
RxNorm normalized name: L. crispatus,gasseri,jensenii,rhamnosus/B. infantis 6 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. crispatus G14‐5M (2 g twice daily for one month)
Trial: 36193094
Drug: L. helveticus
RxNorm normalized name: L. helveticus,rhamnosus/B. longum/zinc yeast/selenium yeast 2 billion cell-2 mg-12.5 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. helveticus M2‐09‐R02‐S146 (2 g twice daily for one month)
Trial: 36193094
Drug: L. plantarum
RxNorm normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. plantarum CCFM8610 (2 g twice daily for one month)
Trial: 33341950
Drug: Health information
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health information via a tablet computer plus 10 live health coaching sessions delivered virtually (intervention group; n=125)
Trial: 33341950
Drug: Health information
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health information via a tablet only (control group; n=125)
Trial: 36447142
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) injected on embryo transfer day
Trial: 32498771
Drug: Tablet-based control
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based control intervention with comparable audio, visual, and tactile components
Trial: 35576073
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg once daily for 3 months or until stone free
Trial: 35576073
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 3 months or until stone free
Trial: 33954805
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg/kg)
Trial: 34715934
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day ergothioneine for 12 weeks
Trial: 34715934
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day ergothioneine for 12 weeks
Trial: 32726103
Drug: Iron-oxide containing
RxNorm normalized name: IRON OXIDES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-oxide containing formulations
Trial: 32086888
Drug: Zhuyuan soup
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuyuan soup combined with fumigation and oral administration
Trial: 32086888
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray (western medicine group)
Trial: 32511534
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no inhalation of NO)
Trial: 33861194
Drug: Adrenaline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (1 mg)
Trial: 36063792
Drug: Goal-directed care
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed care bundle of intensive blood pressure lowering, glycemic control, antipyrexia, and anticoagulation reversal treatment
Trial: 32981468
Drug: Concurrent complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent complex training (CPX)
Trial: 32270496
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL crystalloid fluid bolus over 30 minutes
Trial: 616593029
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behavioral therapy (ICBT) program
Trial: 32334602
Drug: Benzodiazepines or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines or z-hypnotics dispensed
Trial: 32334602
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily dose of benzodiazepines or z-hypnotics
Trial: 32334602
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily dose of pregabalin
Trial: 32334602
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of gabapentinoids with benzodiazepines or z-hypnotics
Trial: 32334602
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of non-OAT opioids with benzodiazepines or z-hypnotics
Trial: 35998897
Drug: Calanus oil
RxNorm normalized name: CALANUS OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calanus oil (2 g/day)
Trial: 34700446
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment arm (74 Gy)
Trial: 34700446
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment arm (60 Gy)
Trial: 34700446
Drug: Dose to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to cardiac sub-regions
Trial: 34700446
Drug: Mean lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean lung dose
Trial: 34223605
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy for 52 weeks
Trial: 32638173
Drug: Systemic enzyme
RxNorm normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic enzyme therapy (SET) administered 48 hours prior to surgery
Trial: 32638173
Drug: Systemic enzyme
RxNorm normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic enzyme therapy (SET) started on the day of surgery
Trial: 32638173
Drug: Systemic enzyme
RxNorm normalized name: alpha-D-galactosidase enzyme Chewable Tablet [Beano]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic enzyme therapy (SET) started immediately after surgery
Trial: 36447152
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with paclitaxel/cisplatin/5‐fluorouracil (TPF) followed by concurrent chemoradiotherapy (CCRT)
Trial: 32702334
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for 6 months
Trial: 34514635
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line treatment according to national guidelines
Trial: 34514635
Drug: New and
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New and better treatments introduced
Trial: 34712863
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg daily for 42 days)
Trial: 36458825
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg)
Trial: 32167550
Drug: Ultrasound-guided glossopharyngeal
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided glossopharyngeal nerve block (UGPNB) with 1.5 mL of 0.5% ropivacaine and 20 mg of methylprednisolone
Trial: 36091794
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g LSZ capsules three times a day for 90 days
Trial: 36091794
Drug: Placebo LSZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo LSZ capsules for 90 days
Trial: 35180283
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (medication advice, rehabilitation exercise, nurse follow-up)
Trial: 35067660
Drug: 1-drop regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-drop regimen of intracameral delivery of moxifloxacin and dexamethasone suspension and topical bromfenac for 30 days
Trial: 35067660
Drug: 3-drop regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-drop regimen of topical moxifloxacin 0.5% 4 times a day for 7 days, bromfenac 0.07% daily for 30 days, and prednisolone acetate 1% 4 times a day for 30 days
Trial: 36106312
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.3% ropivacaine (Group L)
Trial: 36106312
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.5% ropivacaine (Group H)
Trial: 34444999
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) - maintained their daily routine
Trial: 33596494
Drug: Ayurvedic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic treatment regime (1 g Giloy Ghanvati, 2 g Swasari Ras, 0.5 g Ashwagandha, 0.5 g Tulsi Ghanvati, and 4 drops of Anu taila)
Trial: 33596494
Drug: Placebo (identical-looking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical-looking tablets and drops)
Trial: 34695064
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) 150 mg/kg
Trial: 35559241
Drug: Probiotic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplements
Trial: 33585896
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 × 150 mg/day)
Trial: 33585896
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 × 150 mg/day)
Trial: 32069044
Drug: Compounds with
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounds with the lowest 130 reorganization energy
Trial: 34774538
Drug: Carboxymethylcellulose (CMC)
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose (CMC) 15 g per day
Trial: 34537057
Drug: Abatacept 125
RxNorm normalized name: abatacept 125 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 125 mg weekly
Trial: 33705695
Drug: Secondary cytoreduction
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary cytoreduction followed by chemotherapy (six 3-weekly cycles of intravenous paclitaxel [175 mg/m2] or docetaxel [75 mg/m2] combined with intravenous carboplatin [AUC 5 mg/mL per min])
Trial: 33705695
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (no surgery group)
Trial: 33705695
Drug: Secondary cytoreduction
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary cytoreduction followed by chemotherapy
Trial: 36318025
Drug: Amoxicillin with
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin with clavulanate for one week before surgery
Trial: 33514447
Drug: Brief problem
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief problem solving therapy (PST) delivered in four sessions over a maximum period of eight weeks
Trial: 33514447
Drug: Brief problem
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief problem solving therapy (PST)
Trial: 32214298
Drug: Nebulized ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized ketamine 3 mg/kg
Trial: 34582670
Drug: CCRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT with weekly cisplatin followed by observation (arm A)
Trial: 33034099
Drug: Althaea officinalis
RxNorm normalized name: Althaea officinalis root
DrugBank: Althea root (DB13525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Althaea officinalis 1% ointment
Trial: 32347684
Drug: Guidance document
RxNorm normalized name: ZINC OXIDE 120 mg in 1 mL TOPICAL CREAM [GUIDANCE TO GLOW TRU SPF 35]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidance document recommendations on diagnosis and treatment of LGG patients
Trial: 35946416
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + COPD Education (COPD‐ED)
Trial: 35946416
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + Attention Control (AC)
Trial: 32580188
Drug: Roxadustat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxadustat (50 mg, n = 49; 70 mg, n = 50)
Trial: 35491524
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg with exenatide-matched placebo
Trial: 35134184
Drug: Exenatide twice
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice daily 10 µg with dapagliflozin-matched placebo
Trial: 33819172
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (testing for STIs and providing information on treatment facilities)
Trial: 33143690
Drug: Quadrivalent HPV6/11/16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV6/11/16/18 vaccine (vaccinated group)
Trial: 35807803
Drug: Experimental milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental milk-based formula (EF) containing five HMOs (5.75 g/L; 2′‐FL, 3‐FL, LNT, 3′‐SL and 6′‐SL)
Trial: 35595781
Drug: Rivaroxaban (factor-Xa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (factor-Xa inhibitor)
Trial: 33491327
Drug: Pseudoephedrine 120
RxNorm normalized name: CTM 8/PSEUDOEPHEDRINE 120MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D)
Trial: 35412603
Drug: Japanese encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese encephalitis (JE) vaccine
Trial: 35796651
Drug: Sitagliptin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin plus saline infusion
Trial: 35796651
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment + GIP(3‐30)NH2
Trial: 32940683
Drug: Preparation for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation for dialysis
Trial: 32940683
Drug: Preparation for
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation for conservative care
Trial: 35095084
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with ambrisentan and tadalafil
Trial: 36050542
Drug: As B
RxNorm normalized name: Octaplas B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As B but with additional telephone follow-up once weekly for 6 weeks